MX2020003546A - Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. - Google Patents

Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.

Info

Publication number
MX2020003546A
MX2020003546A MX2020003546A MX2020003546A MX2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A MX 2020003546 A MX2020003546 A MX 2020003546A
Authority
MX
Mexico
Prior art keywords
treatment
methods
pharmaceutical formulation
extended release
release pharmaceutical
Prior art date
Application number
MX2020003546A
Other languages
English (en)
Inventor
Paul William Glue
Natalie June Medlicott
Peter William Surman
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/728,695 external-priority patent/US10441544B2/en
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of MX2020003546A publication Critical patent/MX2020003546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona una formulación oral de liberación prolongada para el tratamiento de la depresión resistente al tratamiento, la ansiedad resistente al tratamiento y la fobia.
MX2020003546A 2017-10-10 2018-10-10 Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento. MX2020003546A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/728,695 US10441544B2 (en) 2017-10-10 2017-10-10 Extended release pharmaceutical formulation
US201862695966P 2018-07-10 2018-07-10
PCT/IB2018/057851 WO2019073408A1 (en) 2017-10-10 2018-10-10 PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS

Publications (1)

Publication Number Publication Date
MX2020003546A true MX2020003546A (es) 2020-08-03

Family

ID=66101315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003546A MX2020003546A (es) 2017-10-10 2018-10-10 Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.

Country Status (8)

Country Link
US (2) US20220347104A1 (es)
EP (1) EP3694832A4 (es)
JP (1) JP7364558B2 (es)
CN (1) CN111630026A (es)
AU (1) AU2018348359C1 (es)
CA (1) CA3077645A1 (es)
MX (1) MX2020003546A (es)
WO (1) WO2019073408A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
WO2020194087A2 (en) * 2019-03-25 2020-10-01 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US20210052517A1 (en) * 2017-10-10 2021-02-25 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) * 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022504036A (ja) 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
CA3152593A1 (en) * 2019-12-20 2021-06-24 Tong-Ho Lin Long-acting injectable formulations of ketamine pamoate salts
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
WO2021137147A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
CA2751627A1 (en) * 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
CN107412173A (zh) * 2010-12-23 2017-12-01 普渡制药公司 抗篡改固体口服剂型
EP3804811A1 (en) * 2013-05-13 2021-04-14 Icahn School of Medicine at Mount Sinai Treatment of mood and anxiety disorders
CA2922507C (en) * 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
SI3215147T1 (sl) * 2014-11-04 2024-05-31 Acadia Pharmaceuticals Inc. Nevroatenuacijske spojine norketamina in postopki
US11471415B2 (en) * 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment

Also Published As

Publication number Publication date
US20220354798A1 (en) 2022-11-10
WO2019073408A1 (en) 2019-04-18
AU2018348359A1 (en) 2020-04-23
EP3694832A4 (en) 2021-07-14
AU2018348359B2 (en) 2023-07-13
AU2018348359C1 (en) 2023-10-12
JP7364558B2 (ja) 2023-10-18
EP3694832A1 (en) 2020-08-19
JP2020536901A (ja) 2020-12-17
AU2018348359A8 (en) 2020-04-30
CA3077645A1 (en) 2019-04-18
US20220347104A1 (en) 2022-11-03
CN111630026A (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
MX2020003546A (es) Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
BR112019007806A2 (pt) composição bucal de múltiplas fases para a liberação de agentes ativos para tratamento bucal
CL2018002359A1 (es) Métodos para usar agonistas de fxr
ECSP19078196A (es) Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
CL2017000824A1 (es) Moduladores de regulador de conducta de transmembranas de fibrosis cística
ECSDI18019182S (es) Dispositivo intranasal para suministro de fármacos
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016002495A1 (es) Derivados de piridina macrocíclicos .
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12016501841A1 (en) Immunosuppressant formulation
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2017000151A1 (es) Derivados de piridona
CL2019001038A1 (es) Composición para el cuidado bucal.
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas